Noninvasive Biomarker of Variceal Bleeding in HCV Cirrhosis
Although hepatic vein pressure gradient measurement is an accurate method for evaluation of portal HTN, this technique is invasive and not widely available.
Hepatitis
Hepatitis
-
-
Treatment Regimens and Recommendations for HIV/HCV Coinfection
Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection. -
The Changing Face of HCV: Role of the Opioid Epidemic
The opioid epidemic has fueled the transmission of HCV, particularly among younger persons, who are often unaware of their risks and prevented from receiving timely treatment due to a variety of care barriers, even in settings ideally suited to identifying and treating HCV. -
Racial Disparities in HCV Incidence and Treatment Outcomes
Racial disparities in HCV treatment outcomes can be partially explained by the differences in underlying immune/genetic characteristics of patients. -
Short-Duration Treatment Regimens for Chronic HCV: Latest Insights
The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved treatment adherence, and a reduced rate of side effects.
Latest News
Age, Race, and Genotype Associated With Hepatitis B Envelope Antigen Prevalence
Hepatitis B e antigen prevalence and other hepatitis B virus markers decline with age and differ by race with HBeAg persisting longer among Asian people.
Glecaprevir/Pibrentasvir Approved to Treat All 6 Genotypes of HCV in Pediatric Patients
The FDA has approved Mavyret for the treatment of all 6 genotypes of hepatitis C virus in children 12 to 17 years old or weighing at least 45kg.
Directly Observed Therapy Improves HCV Care in Opioid Agonist Programs
In onsite HCV care delivered to PWID in opioid agonist therapy programs, a greater adherence was associated with directly observed therapy when compared with self-administered individual treatment.
Glecaprevir + Pibrentasvir: Efficacious, Safe for HCV After Liver Transplantation
An 8- or 12-week regimen of glecaprevir and pibrentasvir is efficacious and safe in patients with HCV infection after liver transplantation.
DAA Treatment Before Liver Transplantation May Improve Outcome
Treatment with DAAs before liver transplantation is associated with improved outcome and appears to be safe in patients with decompensated hepatitis C-related cirrhosis.
No Significant Effect on Maternal/Fetal Bone Mineral Density With Maternal TDF Use
There was no significant effect of maternal tenofovir use for the prevention of mother-to-child transmission of HBV on bone mineral density in either the mother or child 1 year after delivery.
Antiviral Therapy May Prevent Liver Injury in Hepatitis B/TB Co-Infection
Patients with TB and HBV co-infection should be given antiviral treatment for HBV when anti-TB therapy is initiated.
Direct-Acting Antiviral Therapy and Recurrence of Hepatitis C-Related Hepatocellular Carcinoma
The impact of direct-acting antiviral therapy was investigated in a large cohort of patients in complete remission following treatment of hepatitis C-related HCC.
Occult Hepatitis B in Hepatitis C-Associated Hepatocellular Carcinoma
Occult hepatitis B virus infection was detected in 50% of patients with chronic hepatitis C with CHC-related hepatocellular carcinoma.
Benefits of Expanding HCV Treatment Outweigh Short-Term Costs for State Medicaid Programs
Findings suggest that states should consider revising their HCV treatment policies to include all individuals infected with HCV to achieve significant patient- and population-level benefits.
AGA Clinical Practice Update: DAAs for Hepatitis C and Hepatocellular Cancer
The AGA present an updated summary of best practice advice for surveillance of hepatocellular cancer and DAA therapy timing.
HCV Reinfection Rate a Concern Among MSM With HIV in Madrid
Data suggests that prevention strategies and frequent testing with HCV-RNA should be applied after sustained virologic response in MSM who engage in high-risk practices.
Progress Achieved in Hepatitis B Control in Western Pacific Region
Report describes progress made to achieve hepatitis B control in the Western Pacific Region and the steps taken to eliminate mother-to-child transmission of hepatitis B virus during 2005 to 2017.
Update for Controlling Widespread Hepatitis A Outbreaks
An update to the Health Alert Network advisory that was released in June 2018 was issued by the CDC on March 25th.
Pegylated Interferon α-2b Plus Ribavirin Effective for HCV Genotypes 2, 3
Investigators evaluated the real-life efficacy of pegylated interferon α-2b with ribavirin in treatment-naive patients with chronic genotypes 2 or 3 hepatitis C virus infection.
A Global Meta-Analysis on HIV, HCV, and HBV in People Who Inject Drugs
Investigators assessed country, regional, and global incidence of serologically confirmed HIV, anti-hepatitis C virus, and hepatitis B virus prevalence according to gender in people who inject drugs.
Liver Stiffness Plus Hyaluronic Acid Measurements Improve Prognostic Ability
Investigators examined the effectiveness of combined noninvasive methods to forecast outcomes in patients with chronic liver diseases.
Ledipasvir/Sofosbuvir ± Ribavirin Effective, Safe in HCV With Advanced Liver Disease
A combination treatment of ledipasvir/sofosbuvir with or without ribavirin was an effective and tolerable treatment in patients with chronic hepatitis C and advanced liver disease before and after liver transplantation.
High Response Seen for All Hep C Treatment Models in Injection Drug Users
For people with HCV who inject drugs and receive opioid agonist therapy, receipt of HCV treatment is associated with high sustained virologic response.
Optimal Limit of Detection for a Point-of-Care HCV Viremia Test
Dataset of 66,640 individuals from 12 countries representative of 6 global regions confirmed that a test with a limit of detection of 1318 IU/mL would identify 97% of viremic HCV infections.
Want to read more?
Please login or register first to view this content.
Next post in Hepatitis
